No products in the cart.
Pre-made Dupilumab benchmark antibody ( Whole mAb, anti-IL4R therapeutic antibody, Anti-CD124 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-158
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Dupilumab biosimilar, Whole mAb, Anti-IL4R Antibody: Anti-CD124 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody used for allergic diseases such as eczema (atopic dermatitis), asthma and nasal polyps which result in chronic sinusitis.
| Products Name (INN Index) | Pre-Made Dupilumab biosimilar, Whole mAb, Anti-IL4R Antibody: Anti-CD124 therapeutic antibody |
|---|---|
| INN Name | Dupilumab |
| Target | IL4R |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 6wgb:AB:CD/6wgj:AB:CD:EF/6wgk:AB:CD:EF:GH/6wgl:AB/6wg8:AB |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2012 |
| Year Recommended | 2013 |
| Companies | Aimmune Therapeutics,Regeneron Pharmaceuticals,Sanofi |
| Conditions Approved | Asthma,Atopic dermatitis,Nasal polyps |
| Conditions Active | Chronic obstructive pulmonary disease,Eosinophilic oesophagitis,Grass pollen hypersensitivity,Peanut hypersensitivity,Urticaria |
| Conditions Discontinued | Allergic asthma |
| Development Tech | VelocImmune Mouse |
| Previous Name | NA |
| Gm Offical Target Name | IL4R |
| Package |
Previous slide
Next slide
